Investors who have held shares of Moderna (NASDAQ: MRNA) for a while have had a difficult year. The company's stock is down by 48% year to date. But it's often helpful to zoom out, and in the past three years, the vaccine maker has performed splendidly, rising by a whopping 737% in this period.

Still, Moderna's showing this year is a bit scary, and some investors may fear the sell-off may get worse and, eventually, wipe out all of the biotech's gains in recent years. By contrast, if Moderna can turn things around, it is worthwhile to hold its shares through these challenging times. 

Hence the question, is it too late to get in on Moderna?

Continue reading

Source Fool.com